{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide-statins","title":"semaglutide statins","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semaglutide-statins/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c2","text":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c3","text":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","tier":"mechanistic","weight":0.3,"section":"what_is_known","slot":"what_is_known","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c4","text":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c5","text":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c6","text":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s6"],"source_status":"sourced","why_material":"Materialized from orphan source s6 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c7","text":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s7"],"source_status":"sourced","why_material":"Materialized from orphan source s7 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c8","text":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s8"],"source_status":"sourced","why_material":"Materialized from orphan source s8 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c9","text":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s9"],"source_status":"sourced","why_material":"Materialized from orphan source s9 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c_map_semaglutide-statins","text":"Combinatorial mapping (transparent): semaglutide vs statins — regen=0.32, degen=0.45, Δ=-0.13. Method: layer_relevance(0.60) × evidence_factor(0.40); catalog.degen_score for Statins.","section":"what_is_known","tier":"runtime","weight":0.35,"stance_scores":{}}],"sources":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","author":"","publisher":"","date":"","claim_ids":["c1"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:25.627Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5","source_role":"core_stack_evidence"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","author":"","publisher":"","date":"","claim_ids":["c2"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:45.532Z","link_status":"ok","quote_status":"verified","prev":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5","hash":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1","source_role":"core_stack_evidence"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","summary":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","author":"","publisher":"","date":"","claim_ids":["c3"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:45.532Z","link_status":"ok","quote_status":"verified","prev":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1","hash":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3","source_role":"core_stack_evidence"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","author":"","publisher":"","date":"","claim_ids":["c4"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"verified","prev":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3","hash":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb","source_role":"core_stack_evidence"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","summary":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","author":"","publisher":"","date":"","claim_ids":["c5"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"unverified","prev":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb","hash":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968","source_role":"core_stack_evidence"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","summary":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","author":"","publisher":"","date":"","claim_ids":["c6"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"unverified","prev":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968","hash":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4","source_role":"core_stack_evidence"},{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","author":"","publisher":"","date":"","claim_ids":["c7"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4","hash":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f","source_role":"core_stack_evidence"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","summary":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","author":"","publisher":"","date":"","claim_ids":["c8"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f","hash":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db","source_role":"core_stack_evidence"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","summary":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","author":"","publisher":"","date":"","claim_ids":["c9"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db","hash":"47911d0481591ba31783e80cc560ef599eaac7c3360fd26887039bd11d8a73b1","source_role":"core_stack_evidence"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":4,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T18:00:05.702Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"semaglutide statins","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"6cdb99f806135738078469421ec8ae87af768258a7b7660883e3e8561e96f17f"},{"seq":1,"id":"k2","ts":"2026-06-29T18:00:25.851Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"6cdb99f806135738078469421ec8ae87af768258a7b7660883e3e8561e96f17f","hash":"822c30229d3458115e4bd9d5940c73a902861238c9a64cb48e80b1b3ba2d3481"},{"seq":2,"id":"k3","ts":"2026-06-29T18:00:46.693Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"822c30229d3458115e4bd9d5940c73a902861238c9a64cb48e80b1b3ba2d3481","hash":"9f61d36676ad5550610e87fee6e82dd9181f950a5649f05d4fea47d0010045c4"},{"seq":3,"id":"k4","ts":"2026-06-29T18:01:05.441Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 3","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"9f61d36676ad5550610e87fee6e82dd9181f950a5649f05d4fea47d0010045c4","hash":"e5e4e5116647a95b6e79870d7a85e187fad41eceb1d17ac103fbac0c04fbe09f"},{"seq":4,"id":"k5","ts":"2026-06-29T18:01:29.091Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","link_status":"ok","quote_status":"verified"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 4","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"e5e4e5116647a95b6e79870d7a85e187fad41eceb1d17ac103fbac0c04fbe09f","hash":"52dfa5581db57c32892efae901255ddc40ae6a6f2b4af89513bd4305d5d8457b"}],"provenance":[{"ts":"2026-06-29T18:00:05.702Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"bccbd81eeeb1f5ae2e4782f95e87c3fe13df7e226114ac1fb41c0413293c759d"},{"ts":"2026-06-29T18:00:25.851Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bccbd81eeeb1f5ae2e4782f95e87c3fe13df7e226114ac1fb41c0413293c759d","hash":"800a1a822d0c41dba73313b2800748e532bd43a8ff7f43677f8e9c77987c4e25"},{"ts":"2026-06-29T18:00:46.693Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"800a1a822d0c41dba73313b2800748e532bd43a8ff7f43677f8e9c77987c4e25","hash":"81c6aed24ea08b1874f14254af5eeb7e7b1cb218a4c8d803cd4d224a36e842c1"},{"ts":"2026-06-29T18:01:05.441Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"81c6aed24ea08b1874f14254af5eeb7e7b1cb218a4c8d803cd4d224a36e842c1","hash":"d5fc60ed11f963825e38892a2f73533447527d55919242158d7a9f63b7aa1593"},{"ts":"2026-06-29T18:01:29.091Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d5fc60ed11f963825e38892a2f73533447527d55919242158d7a9f63b7aa1593","hash":"67e6e929f2d3cd4e3ed603a56f651e4d9a7fafa1efbc5a62d240ac41a00c9d64"},{"ts":"2026-07-17T02:41:49.415Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide-statins","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"67e6e929f2d3cd4e3ed603a56f651e4d9a7fafa1efbc5a62d240ac41a00c9d64","hash":"b544ec6063a65678c03ac4df83333ed463c075b2d31c2c363f7950561f52be4e"}],"energy":{"passes":6,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":5,"owner":1},"head":"b544ec6063a65678c03ac4df83333ed463c075b2d31c2c363f7950561f52be4e"},"posted_at":"2026-06-29T18:00:05.702Z","created_at":"2026-06-29T18:00:05.702Z","updated_at":"2026-07-17T02:41:49.415Z","machine":{"shape":"article.machine/v1","slug":"semaglutide-statins","kind":"article","read":{"human":"https://miscsubjects.com/a/semaglutide-statins","json":"https://miscsubjects.com/api/articles/semaglutide-statins","bundle":"https://miscsubjects.com/api/articles/semaglutide-statins/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":10,"sources":9,"contributions":5,"revisions":4,"objections_url":"https://miscsubjects.com/api/articles/semaglutide-statins/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semaglutide-statins","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-statins\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-statins\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semaglutide-statins/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semaglutide-statins\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semaglutide-statins | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semaglutide-statins","json":"/api/articles/semaglutide-statins","markdown":"/api/articles/semaglutide-statins/bundle?format=markdown","skill":"/api/articles/semaglutide-statins/skill","topology":"/api/articles/semaglutide-statins/topology","versions":"/api/articles/semaglutide-statins/revisions","invocations":"/api/articles/semaglutide-statins/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semaglutide-statins","ok":false,"issues":[{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061","object":{"object_type":"article-object","identity":{"id":"article:semaglutide-statins","slug":"semaglutide-statins","title":"semaglutide statins"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/semaglutide-statins","role":"explain","audience":"human"},"skill":{"route":"/api/articles/semaglutide-statins/skill","role":"direct behavior","audience":"model","content":"---\nname: semaglutide-statins\ndescription: Apply the semaglutide statins article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# semaglutide statins\n\nThis Skill is the behavioral expression of [the canonical article](/a/semaglutide-statins). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/semaglutide-statins.\n- Read claims and relationships at /api/articles/semaglutide-statins/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nOverview Evidence is being populated by Grok web search.\n\n## Representations\n\n- Human: /a/semaglutide-statins\n- JSON: /api/articles/semaglutide-statins\n- Relationships: /api/articles/semaglutide-statins/topology\n- History: /api/articles/semaglutide-statins/revisions\n"},"json":{"route":"/api/articles/semaglutide-statins","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/semaglutide-statins/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["semaglutide","statins"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/semaglutide-statins/invocations?status=success","failure_events":"/api/articles/semaglutide-statins/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"semaglutide-statins","title":"semaglutide statins","body":"## Overview\nEvidence is being populated by Grok web search.","hero":null,"images":[],"style":{},"tags":[],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/semaglutide-statins/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c2","text":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s2"],"source_status":"sourced","why_material":"Materialized from orphan source s2 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c3","text":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","tier":"mechanistic","weight":0.3,"section":"what_is_known","slot":"what_is_known","source_ids":["s3"],"source_status":"sourced","why_material":"Materialized from orphan source s3 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c4","text":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s4"],"source_status":"sourced","why_material":"Materialized from orphan source s4 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c5","text":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c6","text":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s6"],"source_status":"sourced","why_material":"Materialized from orphan source s6 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c7","text":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s7"],"source_status":"sourced","why_material":"Materialized from orphan source s7 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c8","text":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s8"],"source_status":"sourced","why_material":"Materialized from orphan source s8 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c9","text":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","tier":"human","weight":0.8,"section":"what_is_known","slot":"what_is_known","source_ids":["s9"],"source_status":"sourced","why_material":"Materialized from orphan source s9 by ledger repair","status":"active","who_claims":"grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"populate-repair","ts":"2026-06-29T18:01:29.125Z","model":"grok/grok-4.3","rationale":""},"source_role":"core_stack_evidence"},{"id":"c_map_semaglutide-statins","text":"Combinatorial mapping (transparent): semaglutide vs statins — regen=0.32, degen=0.45, Δ=-0.13. Method: layer_relevance(0.60) × evidence_factor(0.40); catalog.degen_score for Statins.","section":"what_is_known","tier":"runtime","weight":0.35,"stance_scores":{}}],"sources":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.","author":"","publisher":"","date":"","claim_ids":["c1"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:25.627Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5","source_role":"core_stack_evidence"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.","author":"","publisher":"","date":"","claim_ids":["c2"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:45.532Z","link_status":"ok","quote_status":"verified","prev":"07e650f34f3ff9c3bea8422277d4dc08e4c7acd68a68c815ef5f653aa5f38bc5","hash":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1","source_role":"core_stack_evidence"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","summary":"Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.","author":"","publisher":"","date":"","claim_ids":["c3"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:00:45.532Z","link_status":"ok","quote_status":"verified","prev":"e2c0d2975e46dbb1e7afae6e4f212e665ff2c7b9533efd8191441dbe45dadaf1","hash":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3","source_role":"core_stack_evidence"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","summary":"2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.","author":"","publisher":"","date":"","claim_ids":["c4"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"verified","prev":"fd7943666a0523bbbfda490dd3e75ff542f0f8031aef1c157195c10b89ced8f3","hash":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb","source_role":"core_stack_evidence"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","summary":"2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.","author":"","publisher":"","date":"","claim_ids":["c5"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"unverified","prev":"cd5f3279adf9bf57663e26a244d1ae9330cc6672053f5586dd2ff6ca6342d1eb","hash":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968","source_role":"core_stack_evidence"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","summary":"2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).","author":"","publisher":"","date":"","claim_ids":["c6"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:05.115Z","link_status":"ok","quote_status":"unverified","prev":"59488764d2ab2da2fcbc51da92fb744d07d05368a77cf32abff938f4e4de4968","hash":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4","source_role":"core_stack_evidence"},{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","summary":"Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.","author":"","publisher":"","date":"","claim_ids":["c7"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"bbe408d9ac9a029cf51f511acfebf5b2ff78442351927b655e432bf7f7294cd4","hash":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f","source_role":"core_stack_evidence"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","summary":"Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.","author":"","publisher":"","date":"","claim_ids":["c8"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"2c173939591889829ff818c2a8f4a323b6a15bdc9dca923fafe5797ecd30658f","hash":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db","source_role":"core_stack_evidence"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","summary":"Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.","author":"","publisher":"","date":"","claim_ids":["c9"],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T18:01:28.935Z","link_status":"ok","quote_status":"verified","prev":"51d44659e74617153b5eed278699548b10b4bc642e91e50dfac5077f3a0a25db","hash":"47911d0481591ba31783e80cc560ef599eaac7c3360fd26887039bd11d8a73b1","source_role":"core_stack_evidence"}],"reviews":[],"extra":{},"has_traversal":false,"register":"standard","status":"published","revisions":4,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T18:00:05.702Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"semaglutide statins","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"6cdb99f806135738078469421ec8ae87af768258a7b7660883e3e8561e96f17f"},{"seq":1,"id":"k2","ts":"2026-06-29T18:00:25.851Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"medical","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"6cdb99f806135738078469421ec8ae87af768258a7b7660883e3e8561e96f17f","hash":"822c30229d3458115e4bd9d5940c73a902861238c9a64cb48e80b1b3ba2d3481"},{"seq":2,"id":"k3","ts":"2026-06-29T18:00:46.693Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40866272/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40284475/","title":"Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles","quote":"The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"822c30229d3458115e4bd9d5940c73a902861238c9a64cb48e80b1b3ba2d3481","hash":"9f61d36676ad5550610e87fee6e82dd9181f950a5649f05d4fea47d0010045c4"},{"seq":3,"id":"k4","ts":"2026-06-29T18:01:05.441Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40166440/","title":"Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy","quote":"Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/","title":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis","quote":"This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/","title":"Cardiovascular outcomes of semaglutide and tirzepatide for ...","quote":"Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 3","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"9f61d36676ad5550610e87fee6e82dd9181f950a5649f05d4fea47d0010045c4","hash":"e5e4e5116647a95b6e79870d7a85e187fad41eceb1d17ac103fbac0c04fbe09f"},{"seq":4,"id":"k5","ts":"2026-06-29T18:01:29.091Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s7","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/","title":"Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab","quote":"We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.","link_status":"ok","quote_status":"verified"},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/","title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","quote":"Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/","title":"Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","quote":"For example, statins were used in more than 80% of enrolled participants","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 4","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"e5e4e5116647a95b6e79870d7a85e187fad41eceb1d17ac103fbac0c04fbe09f","hash":"52dfa5581db57c32892efae901255ddc40ae6a6f2b4af89513bd4305d5d8457b"}],"provenance":[{"ts":"2026-06-29T18:00:05.702Z","model":"grok-4.3","action":"populate-init","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"bccbd81eeeb1f5ae2e4782f95e87c3fe13df7e226114ac1fb41c0413293c759d"},{"ts":"2026-06-29T18:00:25.851Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bccbd81eeeb1f5ae2e4782f95e87c3fe13df7e226114ac1fb41c0413293c759d","hash":"800a1a822d0c41dba73313b2800748e532bd43a8ff7f43677f8e9c77987c4e25"},{"ts":"2026-06-29T18:00:46.693Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"800a1a822d0c41dba73313b2800748e532bd43a8ff7f43677f8e9c77987c4e25","hash":"81c6aed24ea08b1874f14254af5eeb7e7b1cb218a4c8d803cd4d224a36e842c1"},{"ts":"2026-06-29T18:01:05.441Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"81c6aed24ea08b1874f14254af5eeb7e7b1cb218a4c8d803cd4d224a36e842c1","hash":"d5fc60ed11f963825e38892a2f73533447527d55919242158d7a9f63b7aa1593"},{"ts":"2026-06-29T18:01:29.091Z","model":"grok-4.3","action":"sources","prompt":"","input":"semaglutide-statins","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d5fc60ed11f963825e38892a2f73533447527d55919242158d7a9f63b7aa1593","hash":"67e6e929f2d3cd4e3ed603a56f651e4d9a7fafa1efbc5a62d240ac41a00c9d64"},{"ts":"2026-07-17T02:41:49.415Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide-statins","response":"2 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"67e6e929f2d3cd4e3ed603a56f651e4d9a7fafa1efbc5a62d240ac41a00c9d64","hash":"b544ec6063a65678c03ac4df83333ed463c075b2d31c2c363f7950561f52be4e"}],"energy":{"passes":6,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok-4.3":5,"owner":1},"head":"b544ec6063a65678c03ac4df83333ed463c075b2d31c2c363f7950561f52be4e"},"posted_at":"2026-06-29T18:00:05.702Z","created_at":"2026-06-29T18:00:05.702Z","updated_at":"2026-07-17T02:41:49.415Z","machine":{"shape":"article.machine/v1","slug":"semaglutide-statins","kind":"article","read":{"human":"https://miscsubjects.com/a/semaglutide-statins","json":"https://miscsubjects.com/api/articles/semaglutide-statins","bundle":"https://miscsubjects.com/api/articles/semaglutide-statins/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":10,"sources":9,"contributions":5,"revisions":4,"objections_url":"https://miscsubjects.com/api/articles/semaglutide-statins/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=semaglutide-statins","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-statins\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"semaglutide-statins\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/semaglutide-statins/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"semaglutide-statins\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/semaglutide-statins | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/semaglutide-statins","json":"/api/articles/semaglutide-statins","markdown":"/api/articles/semaglutide-statins/bundle?format=markdown","skill":"/api/articles/semaglutide-statins/skill","topology":"/api/articles/semaglutide-statins/topology","versions":"/api/articles/semaglutide-statins/revisions","invocations":"/api/articles/semaglutide-statins/invocations"},"editorial_review":null,"editorial_audit":{"slug":"semaglutide-statins","ok":false,"issues":[{"code":"heading_filing_label","message":"section heading “Overview” is a filing label that gives a cold reader no claim","replacement":"Replace “Overview” with the concrete claim, event, or object introduced in that section."},{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dcd6b7bdb3704e6e308dd7c9e774bd45269f7b4d7d44b04b150e3024d021c061"}}}